期刊文献+

慢性肾脏病矿物质与骨异常的诊治进展 被引量:1

下载PDF
导出
摘要 近年来,终末期肾脏病(ESRD)的病人数以每年10%以上的速度增加,由于受肾源的限制,透析疗法是目前治疗ESRD的主要方法,随着血液净化技术的发展及进步,终末期肾脏病人的生存率和生存质量有了较大的改善,但与其相关的矿物质和骨异常(CKD—MBD)的发生率随着透析时间的延长而增高,而且治疗意识和治疗效果不甚满意,是影响长期透析患者生活质量严重并发症之一,也是肾内科医师要面临的主要课题。本文笔者结合对NKF/DOQI指南的学习及临床实践体会将对其定义、诊断及治疗进展作一综述。
作者 何颖颖 王青
出处 《中国医药导刊》 2011年第4期584-587,共4页 Chinese Journal of Medicinal Guide
  • 相关文献

参考文献18

  • 1刘秀娟,丁仲如,黄国明.肾性骨病的诊疗进展[J].国外医学(泌尿系统分册),2001,21(5):233-234. 被引量:3
  • 2郑法雷,袁群生.肾-骨对话和肾性骨病:机制与治疗进展[J].中国中西医结合肾病杂志,2008,9(2):95-97. 被引量:15
  • 3Moe S,Drtleke T,Cunnlngham J,et al.Definition,evaluation,and classification of renal teodystrophy:aposition slalemen from Kidney Disease-Improving Global Outcomes (KDIGO).Kidney Int,2006;69:1945-1953.
  • 4Moe SM,Drueke T,Lameire N,et al.Chronic kidney disease-mineral-bone disorder:a new paradigm.Adv Chronic Kidney Dis,2007;14:3-12.
  • 5周文彦,倪兆慧.重视慢性肾脏病患者的无力性骨病[J].临床肾脏病杂志,2010(4):151-153. 被引量:2
  • 6Hutchison AJ.Improving phosphate-binder therapy as a way forward.Nephrol Dial Transplant,2004; 19(Suppl):19-24.
  • 7D&Haese PC,Spasovski GB,Sikole A,et al.A multicenter study on the effects of lanthanum carbonate (Fosranol) and calcium carbonate on renal bone disease in dialysis patients.Kidney Int Suppl,2003;(85):73-78.
  • 8高波,魏丛军,刘昌华,徐建中,常美.低钙透析液对血液透析患者冠状动脉血管钙化的影响[J].实用临床医药杂志,2009,13(12):77-78. 被引量:8
  • 9Monier-Faugere MC,Mawad H,Malluche HH.Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.Clin J Am Soc Nephrol,2007;2:1255-1260.
  • 10Goodman WG.Calcimimetic agents and secondary hyper-parathyroidism:rationale for use and results from clinical trials.Pediatr Nephro,2003;18(12):1206-1210.

二级参考文献32

  • 1郭胜根,邹琴,武爱弟,廖湘平.影响维持性血液透析心血管钙化的因素[J].中国医药指南,2008,6(21):17-18. 被引量:3
  • 2王开 ,钱家麒 ,Peter Stenvinkel ,Bengt Lindholm .终末期肾衰竭患者血清胎球蛋白A水平改变与临床预后的关系[J].中华肾脏病杂志,2005,21(2):72-75. 被引量:21
  • 3徐耀文,汪关煜,钱莹,朱萍,吴霞珺,杨泽彬,陈楠.低钙透析联合碳酸钙治疗血透患者高磷血症[J].中国实用内科杂志:临床前沿版,2006,26(6):907-910. 被引量:10
  • 4Block G A, Port F K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in, management [J ]. Am J Kidney Dis, 2000, 35(6) : 1226.
  • 5Moe S M, Reslerovav M, Ketteler M, et al. Role of calcification in inhibitors in the pathogenesis of vascular calcificatior in chronic kidney disease (CKD)[J ]. Kidney International, 2005, 67(6): 2295.
  • 6Schinke T, Karsenty G. Vascular calcification-a passive process in need of inhibitors [ J ]. Nephrol Dial Transplant, 2000, 15(9): 1272.
  • 7Schurgers L J, Soute B A, Vermeer C. Undercarboxylated matrix glaprotein is associated with vascular calcification[J ]. American Heart Association, Inc, 2004, 24(5):e22.
  • 8Kestenbaum B, Sampson I N, Rudser K D, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J]. J Am Soc Nephrol, 2005, 16(2) : 520.
  • 9Catherine C, Martin P, Bloctdet D. Lung, gastirc, and soft tissue uptake of Tc-99mMDP and Ga-67 citrate associated with hypercalcemia[J]. Clin Nucl Med, 2003, 28(6) : 467.
  • 10Leo P, Karen M, John C, et al. Coronary artery calcification scoring by prospectively triggered multidetector-row computed tomography, is it reproducible[J]. Comput Assist Tomogr, 2004, 28(1): 40.

共引文献27

同被引文献15

  • 1赵慧萍,武蓓,隋准,芦丽霞,乔婕,武向兰,王梅.维持性腹膜透析患者血25(OH)D水平及其相关因素分析[J].中国血液净化,2012,11(4):179-183. 被引量:2
  • 2Michael F.Holick.VITAMIN D IN HEALTH AND DISEASE: Vitamin D for Health and in Chronic Kidney Disease[J]. Seminars in Dialysis . 2005 (4)
  • 3Pilz S,Tomaschitz A,Friedl C,et al.Vitamin D status and mortality in chronic kidney disease. Nephrology . 2011
  • 4de Boer Ian H,Kestenbaum Bryan,Shoben Abigail B,Michos Erin D,Sarnak Mark J,Siscovick David S.25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. Journal of the American Society of Nephrology : JASN . 2009
  • 5Wolf M,Shah A,Gutierrez O,Ankers E,Monroy M,Tamez H,Steele D,Chang Y,Camargo C A,Tonelli M,Thadhani R.Vitamin D levels and early mortality among incident hemodialysis patients. Kidney International . 2007
  • 6Ravani Pietro,Malberti Fabio,Tripepi Giovanni,Pecchini Paola,Cutrupi Sebastiano,Pizzini Patrizia,Mallamaci Francesca,Zoccali Carmine.Vitamin D levels and patient outcome in chronic kidney disease. Kidney International . 2008
  • 7Moe S,Drueke T,Cunningham J,et al.Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International . 2006
  • 8Levin A,Bakris G L,Molitch M,Smulders M,Tian J,Williams L A,Andress D L.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International . 2006
  • 9Matias Patrícia Jo?o,Ferreira Carina,Jorge Cristina,Borges Marília,Aires Inês,Amaral Tiago,Gil Célia,Cortez José,Ferreira Aníbal.25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association . 2008
  • 10辛星,万献尧,毕丽岩.维生素D_3及其受体的临床意义[J].医学与哲学(B),2010,31(4):44-45. 被引量:9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部